Skip to main content
OpenTrials
Completed

NCT Number: NCT03005106

StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements

About 70 participants will be enrolled. They will have complex skin defects because of burns caused by heat.

The burns will:

* be on 3-49% of the participant's total body surface area (TBSA) * require surgery for skin replacement * include intact dermal elements

The burns are called deep, partial-thickness thermal burns because the skin was damaged by heat but still has some dermis that was not damaged.

The dermis is the layer of skin under the outer layer (epidermis). It is the thickest layer of the skin that provides strength and flexibility to the skin.

All patients will receive both treatments, but on different areas of their burns. Their wounds will not be compared to other patients. One treatment area on their own body will be compared to the other one.

This will help to find out if StrataGraft is safe and effective for deep partial thickness burns. It will also see if StrataGraft might help healing enough to use it instead of the patient's own healthy skin to repair the damage.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Burn, Thermal Burns Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

University of South Alabama Medical Center, Mobile, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject-specific criteria:

  • Men and women aged ≥ 18 years
  • Written informed consent
  • Sufficient healthy skin identified and reserved as a donor site in the event that the StrataGraft treatment site requires autografting
  • Clinical expectation that the study donor site will heal without grafting
  • Complex skin defects of 3-49% TBSA
  • Total burn may consist of more than one area

Treatment site-specific criteria:

  • Thermal burn(s) with intact dermal elements for which excision and autografting are clinically indicated
  • Total of both study treatment areas can be up to 2000 cm2
  • First excision and grafting of study treatment sites
  • Thermal burn(s) on the torso, arms, or legs

Exclusion criteria

Subject-specific criteria:

  • Pregnant women
  • Prisoners
  • Subjects receiving systemic immunosuppressive therapy
  • Subjects with a known history of malignancy
  • Preadmission insulin-dependent diabetic subjects
  • Subjects with concurrent conditions that in the opinion of the investigator may compromise subject safety or study objectives
  • Expected survival of less than three months
  • Participation in the treatment group of an interventional study within 90 days prior to enrollment

Treatment site-specific criteria:

  • Full-thickness burns
  • Chronic wounds
  • The face, head, neck, hands, feet, buttocks, and area over joints
  • Treatment sites immediately adjacent to unexcised eschar
  • Clinical or laboratory determination of infection at the anticipated treatment sites

Treatment and study plan

StrataGraft Skin Tissue

Biological

StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).

Autograft

Procedure

The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.

Primary outcomes

  1. Percent Area of Treatment Sites Requiring Autografting by Month 3

    Time frame: 3 Months

    Percent area autografted by Month 3 is the sum of the percent areas at each study session/visit, up to and including Study Session 7/Month 3 (± 14 d).

  2. Number of Participants Classified as a Responder (Based on Durable Wound Closure at Month 3)

    Time frame: Month 3

    Wound closure of the treatment site was defined as complete skin re-epithelialization and the absence of drainage. A participant whose StrataGraft treatment site achieves durable wound closure without autograft placement is classified as a responder.

Secondary outcomes

  1. Pain at the Designated Donor Sites by Day 14

    Time frame: Day 3, Day 7 and Day 14, average of the 3 days reported

    Pain scores from the FACES scale range from 0 (no pain) to 5 (worst pain). Pain scores from Day 3, Day 7, and Day 14 (where available) are averaged for the summary statistics.

  2. Total Scar Assessment (POSAS) Score by Observer at Month 3

    Time frame: at Month 3

    Total Score is the sum of the scores for vascularization, pigmentation, thickness, relief, pliability, and surface area. For each of the 6 assessment categories, the scale ranged from 1=normal skin to 10=worst scar imaginable, with the highest possible score of 10. A higher score indicates worse scarring, so the best possible total score for the 6 categories is 6, and the worst possible score is 60.

Sponsors and collaborators

Lead sponsor

Stratatech, a Mallinckrodt Company

Industry

Registry information

Official study title

A Phase III Open-label, Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of StrataGraft Skin Tissue in Promoting Autologous Skin Tissue Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements and for Which Excision and Autografts Are Clinically Indicated

Important dates

Study start
2017
Primary completion
2019
Study completion
2020
First posted
Dec 29, 2016
Registry last updated
Jul 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.